Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study

ABSTRACT: Indacaterol (IND; 150 μg), glycopyrronium (GLY; 50 μg) and mometasone furoate (MF; 160 μg [high-dose ICS] and 80 μg [medium-dose ICS]) have been formulated as a once-daily (o.d.) fixed-dose combination treatment delivered via the Breezhaler® device for the treatment of patients with asthma...

詳細記述

保存先:
書誌詳細
出版年:Respir Res
主要な著者: Watz, Henrik, Hohlfeld, Jens M., Singh, Dave, Beier, Jutta, Diamant, Zuzana, Liu, Jinming, Hua, Shucheng, Abd-Elaziz, Khalid, Pinot, Pascale, Jones, Ieuan, Tillmann, Hanns-Christian
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2020
主題:
Letter to the Editor
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160900/
https://ncbi.nlm.nih.gov/pubmed/32295593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-020-01349-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料